BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16323434)

  • 1. Bacteremia due to Pseudomonas aeruginosa: results from a 3-year national study in the Slovak Republic.
    Koprnova J; Beno P; Korcova J; Mrazova M; Grey E; Liskova A; Harnicarova A; Karvaj M; Koval S; Zak V; Danaj M; Streharova A; Mitterpachova E; Miklosko J; Ondrusova A; Riedl J; Kaiserova E; Prokopova V; Hornova M; Payer J; Rudinsky B; Pevalova L; Bencelova M; Hanzen J; Macekova L; Csölleyova J; Krcmery V
    J Chemother; 2005 Oct; 17(5):470-6. PubMed ID: 16323434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pseudomonas aeruginosa: antimicrobial resistance in clinical isolates. Castellón 2004-2008].
    Pardo Serrano FJ; Tirado Balaguer MD; García Zúñiga ED; Granados Ortega J; Campos Aznar A; Moreno Muñoz R
    Rev Esp Quimioter; 2010 Mar; 23(1):20-6. PubMed ID: 20232020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
    Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
    Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
    Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS; Huband MD; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
    Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa from patients in a teaching hospital, Riyadh, Saudi Arabia, 2001-2005.
    Babay HA
    Jpn J Infect Dis; 2007 May; 60(2-3):123-5. PubMed ID: 17515646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
    Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
    López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
    Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: second national study (2003).
    Sánchez-Romero I; Cercenado E; Cuevas O; García-Escribano N; García-Martínez J; Bouza E;
    Rev Esp Quimioter; 2007 Jun; 20(2):222-9. PubMed ID: 17893760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial resistance of Pseudomonas aeruginosa strains isolated from surgical infections in a 7-year period at a general hospital in Venezuela.
    Rodriguez CN; Rodriguez-Morales AJ; Garcia A; Pastran B; Meijomil P
    Surg Infect (Larchmt); 2006 Jun; 7(3):269-73. PubMed ID: 16875460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Investigation of the frequency of PER-1 type beta-lactamase and antimicrobial resistance rates in nosocomial isolates of Pseudomonas aeruginosa].
    Atilla A; Eroğlu C; Esen S; Sünbül M; Leblebicioğlu H
    Mikrobiyol Bul; 2012 Jan; 46(1):1-8. PubMed ID: 22399165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
    Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
    Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pseudomonas aeruginosa: a multicenter study in 136 hospitals in Spain].
    Bouza E; Garcia-Garrote F; Cercenado E; Marín M; Díaz MS; Sánchez Romero I; Vindel A;
    Rev Esp Quimioter; 2003 Mar; 16(1):41-52. PubMed ID: 12750756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of 2906 Pseudomonasaeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015.
    Walkty A; Lagace-Wiens P; Adam H; Baxter M; Karlowsky J; Mulvey MR; McCracken M; Zhanel GG
    Diagn Microbiol Infect Dis; 2017 Jan; 87(1):60-63. PubMed ID: 28336136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of antimicrobial resistance against Pseudomonas aeruginosa in a French university hospital between 2002 and 2006].
    Minchella A; Molinari L; Alonso S; Bouziges N; Sotto A; Lavigne JP
    Pathol Biol (Paris); 2010 Feb; 58(1):1-6. PubMed ID: 19875241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [E-test to study small inhibitor concentrations, bacterial diversity and to identify presumptively beta-lactamases in strains of Pseudomonas aeruginosa and Acinetobacter baumannii associated with +nosocomial infections].
    Triantafilo V; Fica A; Silva M; Thompson L
    Rev Med Chil; 1997 Feb; 125(2):149-60. PubMed ID: 9430934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.